|
| Current Location：Home > Information > Innovation - the same topic in vitro diagnostic industry |
| Innovation - the same topic in vitro diagnostic industry |
40 billion U.S. dollars, 30 billion yuan, the former is the size of the global in vitro diagnostics market, which is the size of our in vitro diagnostics market. This is enough to explain the gap between the IVD industry in China there was room for improvement.
"Speed up the IVD sector innovation system and the innovative construction of the project, the development of in vitro diagnostics market in China is of great significance." July 8 ~ 10, the second high-level Forum and the National Health Science and Technology Fair in Beijing, new drugs National Conference Centre, in north-controlled Health Biotech Co., Ltd., and President Wu Lebin in the 12th sub-site was entitled "on the IVD industry awareness of independent innovation."
Technology-driven change
With the human genome research in depth, especially in the post-genome era of open, including functional genomics, proteomics and pharmacogenomics, etc., the research results greatly expand the molecular diagnostics field of study, thereby promoting laboratory medicine in disease diagnosis and evaluation prognosis of development, but also makes the competition more intense in vitro diagnostic reagents.
Xiamen University, National Infectious Diseases Diagnostics and Vaccine Research Center Director Shao Ning Xia summarize the current fierce competition in vitro diagnostic reagents for the performance: first, the core technology and innovation as competitive, emerging companies often through technological innovation to attack the large companies; Second, industry concentration enhanced the monopoly of multinational corporations in the global trend of strengthening, in the competition and ever-increasing industry concentration; Third, the growing market demand, industry scale expanding; fourth, along with the technical standards of the International and commercialization process of globalization accelerated; Fifth, innovative technologies and products, competition, requirements continued to develop appropriate standards.
For the development of in vitro diagnostics, XIA Ning Shao that "towards the poles in the development." He explained that the so-called "bipolar" is the first, highly integrated, automated diagnostics equipment to high efficiency equipment, modular composition and assembly line-style automation greatly improve the efficiency of diagnostic laboratories; other is simple, fast easy to spread and on-site rapid diagnostic testing technology, miniaturization of laboratory equipment, simple technology, timely and accurate reporting of results, have become an increasing clinical staff, patients and their families of all ages.
Fortunately, China's IVD industry in various countries, science and technology plan to guide and support the rapidly growing market demand, the state has made great development. Some areas have already reached the international advanced level, some of the blood screening reagents, routine biochemical reagents, also has the strength to compete with foreign products. Diagnostics industry has gradually become the field of biotechnology and medical technology emerging strategic industries.
Combination of innovation and alliance
The global diagnostics business before the three for the Swiss Roche, Abbott and Siemens, the global market, the three will occupy about 40% of the total amount. In China, although the in vitro diagnostic reagent market is 15% to 20% of the rate of growth, but domestic kit is not very high in market share.
"Blazing New Trails, an alliance platform, is the path of China's IVD industry." Wu Lebin said.
It is understood that in May 2008, the Central Health Biotech Co., Ltd. led the North controlled by the Zhongshan University, Chinese Academy of Sciences and other units involved in Biophysics, set up under the "Chinese in vitro diagnostic industry, Chan Xueyan Innovation Alliance", whose purpose is coordination of research institutes, manufacturers and other sectors of interest, integration of resources, further deepening cooperation.
"Union was established in two years time, in control of lead 承担 Health North State '863 'priority projects' key agents of biomedical' has made gratifying achievements. Now been completed more than 40 product research and development, applied for national patent 11 , international patent, etc. 2. of course, not only due to the contribution of the member units of Alliance, Alliance members have the support of other units. "Wu Lebin said.
The IVD industry innovation system, Wu Lebin that to establish enterprises as the mainstay, market-oriented, government-led industries and academe, with the combination system. At the same time for conditions to satisfy the actual needs of the domestic market as the goal, to the Chinese common disease with a focus on, grasp the cost and price of the border, the most important thing is to ensure product quality.
However, nearly 10 years of the Foreign vitro diagnostic products in the kit - equipment integration, innovative diagnostic products of the target object, a single enterprise within the variety, quality and variety of the equilibrium range and other aspects of the rapid development of in vitro diagnostic industry's overall domestic competitiveness of non- declined.
Faced with this situation, Wu Lebin that should optimize the overall industrial structure, enhance the independent innovation, integrated innovation and re-introduction and assimilation of innovation capacity. Strengthen scientific research institutes and enterprises of solidarity cooperation, 在 get a breakthrough on different projects, such as detection systems, platforms, or base material, reference laboratories Wang Luo Deng Fang Mian. |
| AddTime：2010-7-26 9:06:00 |
Hits：128 |
[Back] |
|
|
|
|
